Publicaciones en colaboración con investigadores/as de Centro de Investigaciones Biológicas (9)

2023

  1. Mutation in Chek2 triggers von Hippel-Lindau hemangioblastoma growth

    Acta Neurochirurgica, Vol. 165, Núm. 12, pp. 4241-4251

2022

  1. A Novel Splicing Mutation in the ACVRL1/ALK1 Gene as a Cause of HHT2

    Journal of Clinical Medicine, Vol. 11, Núm. 11

  2. Propranolol: A “Pick and Roll” Team Player in Benign Tumors and Cancer Therapies

    Journal of Clinical Medicine, Vol. 11, Núm. 15

  3. The Role of Propranolol as a Repurposed Drug in Rare Vascular Diseases

    International Journal of Molecular Sciences, Vol. 23, Núm. 8

2020

  1. CLN5 in heterozygosis may protect against the development of tumors in a VHL patient

    Orphanet Journal of Rare Diseases, Vol. 15, Núm. 1

  2. Review of pharmacological strategies with repurposed drugs for hereditary hemorrhagic telangiectasia related bleeding

    Journal of Clinical Medicine, Vol. 9, Núm. 6, pp. 1-22

  3. Targeting β2-adrenergic receptors shows therapeutical benefits in clear cell renal cell carcinoma from von Hippel–Lindau disease

    Journal of Clinical Medicine, Vol. 9, Núm. 9, pp. 1-30

2019

  1. Evaluation of the safety and effectiveness of oral propranolol in patients with von Hippel-Lindau disease and retinal hemangioblastomas: Phase III clinical trial

    BMJ Open Ophthalmology, Vol. 4, Núm. 1

  2. The β2-adrenergic receptor antagonist ICI-118,551 blocks the constitutively activated HIF signalling in hemangioblastomas from von Hippel-Lindau disease

    Scientific Reports, Vol. 9, Núm. 1